Last reviewed · How we verify

PCV chemotherapy — Competitive Intelligence Brief

PCV chemotherapy (PCV chemotherapy) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy regimen (alkylating agents + vinca alkaloid). Area: Oncology.

phase 3 Chemotherapy regimen (alkylating agents + vinca alkaloid) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

PCV chemotherapy (PCV chemotherapy) — Hospices Civils de Lyon. PCV is a chemotherapy regimen combining procarbazine, lomustine (CCNU), and vincristine to disrupt cancer cell DNA and microtubule function.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
PCV chemotherapy TARGET PCV chemotherapy Hospices Civils de Lyon phase 3 Chemotherapy regimen (alkylating agents + vinca alkaloid)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy regimen (alkylating agents + vinca alkaloid) class)

  1. Hospices Civils de Lyon · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PCV chemotherapy — Competitive Intelligence Brief. https://druglandscape.com/ci/pcv-chemotherapy. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: